|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | |||||||
  Psychiatry and Clinical NeurosciencesVolume 60 Issue 3, Pages 384 - 388 Published Online: 24 May 2006 Journal compilation © 2010 Japanese Society of Psychiatry and Neurology Official Journal of the Japanese Society of Psychiatry and Neurology
Abstract | References | Full Text: HTML, PDF (Size: 51K) | Related Articles | Citation Tracking  Short Communication Topiramate for smoking cessation Copyright © 2006 The Authors; Journal compilation © 2006 Folia Publishing Society KEYWORDS AMPA • glutamate • smoking cessation • smoking • topiramate ABSTRACTAbstract Due to its AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)/kainate antagonism, topiramate would be particularly interesting in addiction treatment. Flexible-dose topiramate was prescribed to 13 smokers (10 smokers who wanted to stop smoking, and three who received topiramate for other reasons). Six out of 13 smokers were abstinent at 2 months and two more subjects had reduced their cigarette consumption by >50%. With one exception, temporary reduction of the number of smoked cigarettes preceded definitive abstinence at month 2. Three more subjects who achieved a momentary reduction had, however, to interrupt the treatment due to intolerable side-effects. Controlled trials are needed to confirm these preliminary observations. Received 30 June 2005; revised 18 October 2005; accepted 13 November 2005. | 
|
